• 1111 Citations

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

My lab studies leukocyte trafficking in the setting of the immune response to tumor development, growth, and treatment. Our focus is on the cellular and molecular mechanisms that are involved in these settings. We utilize mouse tumor models to understand these interactions, and manipulate chemokine/chemokine receptor axes in order to favorably alter the leukocyte profile in the tumor microenvironment. We are investigating a number of different chemokines, but have worked extensively with a novel chemoattractant, chemerin, that we have found is downregulated in a majority of tumors. Forced re-expression of chemerin within the tumor results in reduced tumor growth and increased leukocyte infiltrate. We are working on a number of approaches to translate such findings into clinical use, such as nanoparticles, viral delivery, and novel fusion proteins. Clinically, my focus is on genitourinary immunotherapy, and we have a number of projects related to this. We are actively pursuing novel combinations of immunotherapeutics to test in humans, and plan to do in depth immune monitoring on these patients.

Fingerprint Dive into the research topics where Russell Pachynski is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Cell-free DNA alterations in the AR enhancer and locus predict resistance to AR-directed therapy in patients with metastatic prostate cancer

Dang, H., Chauhan, P. S., Ellis, H., Feng, W., Harris, P. K., Smith, G., Qiao, M., Dienstbach, K., Beck, R., Atkocius, A., Qaium, F., Luo, J., Michalski, J., Picus, J., Pachynski, R., Maher, C. & Chaudhuri, A. A., 2020, In : JCO Precision Oncology. 4, p. 680-713 34 p.

Research output: Contribution to journalArticle

  • 1 Scopus citations

    How else can we approach prostate cancer biomarker discovery?

    Drake, R. R., Angel, P. M., Wu, J., Pachynski, R. K. & Ippolito, J. E., Feb 1 2020, In : Expert Review of Molecular Diagnostics. 20, 2, p. 123-125 3 p.

    Research output: Contribution to journalEditorial

    Open Access
    1 Scopus citations
    Open Access
  • 7 Scopus citations

    Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study

    Martínez Chanzá, N., Xie, W., Asim Bilen, M., Dzimitrowicz, H., Burkart, J., Geynisman, D. M., Balakrishnan, A., Bowman, I. A., Jain, R., Stadler, W., Zakharia, Y., Narayan, V., Beuselinck, B., McKay, R. R., Tripathi, A., Pachynski, R., Hahn, A. W., Hsu, J. A., Shah, S. A., Lam, E. T. & 18 others, Rose, T. L., Mega, A. E., Vogelzang, N., Harrison, M. R., Mortazavi, A., Plimack, E. R., Vaishampayan, U., Hammers, H., George, S., Haas, N., Agarwal, N., Pal, S. K., Srinivas, S., Carneiro, B. A., Heng, D. Y. C., Bosse, D., Choueiri, T. K. & Harshman, L. C., Apr 2019, In : The Lancet Oncology. 20, 4, p. 581-590 10 p.

    Research output: Contribution to journalArticle

  • 29 Scopus citations

    Chemerin suppresses breast cancer growth by recruiting immune effector cells into the tumor microenvironment

    Pachynski, R. K., Wang, P., Salazar, N., Zheng, Y., Nease, L., Rosalez, J., Leong, W. I., Virdi, G., Rennier, K., Shin, W. J., Nguyen, V., Butcher, E. C. & Zabel, B. A., 2019, In : Frontiers in immunology. 10, MAY, 983.

    Research output: Contribution to journalArticle

    Open Access
  • 8 Scopus citations